Frankfurt - Delayed Quote • EUR
Akebia Therapeutics, Inc. (AX9.F)
At close: April 19 at 8:03 AM GMT+2
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 5 | 6 |
| Avg. Estimate | -0.33 | -0.29 | -1.59 | -0.78 |
| Low Estimate | -0.42 | -0.44 | -1.83 | -1.12 |
| High Estimate | -0.27 | -0.16 | -1.47 | -0.37 |
| Year Ago EPS | -0.42 | -0.6 | -2.77 | -1.59 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 6 |
| Avg. Estimate | 47.31M | 54.39M | 208.77M | 272.86M |
| Low Estimate | 35.1M | 45M | 193M | 224.32M |
| High Estimate | 59.7M | 62.8M | 229.21M | 377.07M |
| Year Ago Sales | 59.99M | 56.7M | 295.31M | 208.77M |
| Sales Growth (year/est) | -21.10% | -4.10% | -29.30% | 30.70% |
Earnings History
| CURRENCY IN USD | 9/30/2020 | 12/31/2020 | 3/31/2021 | 6/30/2021 |
|---|---|---|---|---|
| EPS Est. | -0.17 | -0.4 | -0.29 | -0.32 |
| EPS Actual | -0.42 | -0.6 | -0.45 | -0.51 |
| Difference | -0.25 | -0.2 | -0.16 | -0.19 |
| Surprise % | -147.10% | -50.00% | -55.20% | -59.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | -0.33 | -0.29 | -1.59 | -0.78 |
| 7 Days Ago | -0.33 | -0.29 | -1.59 | -0.78 |
| 30 Days Ago | -0.33 | -0.29 | -1.59 | -0.78 |
| 60 Days Ago | -0.3 | -0.29 | -1.35 | -0.78 |
| 90 Days Ago | -0.3 | -0.29 | -1.35 | -0.78 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AX9.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 21.40% | -- | -- | 1.60% |
| Next Qtr. | 51.70% | -- | -- | 10.50% |
| Current Year | 42.60% | -- | -- | 5.20% |
| Next Year | 50.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/28/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/15/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/17/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/27/2023 |
| Upgrade | HC Wainwright & Co.: Neutral to Buy | 8/28/2023 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 8/11/2023 |